Advertisement
Screener

INOVIO PHARMACEUTICALS, INC. (INO) Licenses Revenue (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

INOVIO PHARMACEUTICALS, INC. Licenses Revenue (Deprecated 2018-01-31)

INOVIO PHARMACEUTICALS, INC. (INO) reported Licenses Revenue (Deprecated 2018-01-31) of $1.29 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.

Discontinued › Income Statement › Other Income

us-gaap:LicensesRevenue · last filed 2018-05-09

  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.29M, a 69.94% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $351.27K, a 84.91% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $16.36M, a 765.52% increase year-over-year.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $4.29M, a 138.67% increase year-over-year.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for fiscal 2012 was $82.54K, a 47.23% decline from fiscal 2011.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for fiscal 2011 was $156.40K, a 26.89% decline from fiscal 2010.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for fiscal 2010 was $213.92K, a 95.66% decline from fiscal 2009.
  • INOVIO PHARMACEUTICALS, INC. licenses revenue (deprecated 2018-01-31) for fiscal 2009 was $4.93M.
Period endLicenses Revenue (Deprecated 2018-01-31) 3 monthLicenses Revenue (Deprecated 2018-01-31) 3 month as first filedLicenses Revenue (Deprecated 2018-01-31) 6 monthLicenses Revenue (Deprecated 2018-01-31) 9 monthLicenses Revenue (Deprecated 2018-01-31) 12 month
2018-03-31$1.29M
10-Q · filed 2018-05-09
2017-09-30$351.27K
10-Q · filed 2017-11-08
$16.71M
derived: sum of 2 quarters · filed 2017-11-08
$21.00M
10-Q · filed 2017-11-08
2017-06-30$16.36M
10-Q · filed 2017-08-08
$20.65M
10-Q · filed 2017-08-08
2017-03-31$4.29M
10-Q · filed 2018-05-09
2016-09-30$2.33M
10-Q · filed 2017-11-08
$4.22M
derived: sum of 2 quarters · filed 2017-11-08
$6.01M
10-Q · filed 2017-11-08
2016-06-30$1.89M
10-Q · filed 2017-08-08
$3.69M
10-Q · filed 2017-08-08
2016-03-31$1.80M
10-Q · filed 2017-05-10
2015-09-30$16.48M
10-Q · filed 2016-11-09
$20.81M
derived: sum of 2 quarters · filed 2016-11-09
$25.06M
10-Q · filed 2016-11-09
2015-06-30$4.34M
10-Q · filed 2016-08-08
$8.58M
10-Q · filed 2016-08-08
2015-03-31$4.25M
10-Q · filed 2016-05-09
2014-09-30$1.11M
10-Q · filed 2015-11-09
$4.22M
derived: sum of 2 quarters · filed 2015-11-09
$5.66M
10-Q · filed 2015-11-09
2014-06-30$3.11M
10-Q · filed 2015-08-10
$4.54M
10-Q · filed 2015-08-10
2014-03-31$1.44M
10-Q · filed 2015-05-11
2013-09-30$8.39M
10-Q · filed 2014-11-10
$8.40M
derived: sum of 2 quarters · filed 2014-11-10
$8.42M
10-Q · filed 2014-11-10
$8.54M
derived: sum of 4 quarters · filed 2014-11-10
2013-06-30$14.31K
10-Q · filed 2014-08-11
$28.57K
10-Q · filed 2014-08-11
$149.12K
derived: sum of 3 quarters · filed 2014-08-11
$171.61K
derived: sum of 4 quarters · filed 2014-08-11
2013-03-31$14.26K
10-Q · filed 2014-05-12
$134.81K
derived: sum of 2 quarters · filed 2014-05-12
$157.30K
derived: sum of 3 quarters · filed 2014-05-12
$178.21K
derived: sum of 4 quarters · filed 2014-05-12
2012-12-31$120.55K
10-K · filed 2013-03-18
$143.04K
derived: sum of 2 quarters · filed 2013-11-12
$163.95K
derived: sum of 3 quarters · filed 2013-11-12
$82.54K
10-K · filed 2013-03-18
2012-09-30$22.50K
10-Q · filed 2013-11-12
$43.40K
derived: sum of 2 quarters · filed 2013-11-12
$68.24K
10-Q · filed 2013-11-12
$201.18K
derived: sum of 4 quarters · filed 2013-11-12
2012-06-30$20.91K
10-Q · filed 2013-08-09
$45.74K
10-Q · filed 2013-08-09
$178.68K
derived: sum of 3 quarters · filed 2013-08-09
$361.82K
derived: sum of 4 quarters · filed 2013-08-09
2012-03-31$24.84K
10-Q · filed 2013-05-10
$157.77K
derived: sum of 2 quarters · filed 2013-05-10
$340.91K
derived: sum of 3 quarters · filed 2013-05-10
$472.58K
derived: sum of 4 quarters · filed 2013-05-10
2011-12-31$132.94K
10-K · filed 2013-03-18
$316.07K
derived: sum of 2 quarters · filed 2013-03-18
$447.74K
derived: sum of 3 quarters · filed 2013-03-18
$156.40K
10-K · filed 2013-03-18
2011-09-30$183.14K
10-K · filed 2013-03-18
$76.89K
10-Q · filed 2011-11-07
$314.80K
derived: sum of 2 quarters · filed 2013-03-18
$129.71K
10-Q · filed 2012-11-07
$487.01K
derived: sum of 4 quarters · filed 2013-03-18
2011-06-30$131.66K
10-K · filed 2013-03-18
$26.46K
10-Q · filed 2011-08-05
$52.82K
10-Q · filed 2012-08-09
$303.87K
derived: sum of 3 quarters · filed 2013-03-18
$343.20K
derived: sum of 4 quarters · filed 2013-03-18
2011-03-31$120.12K
10-K · filed 2013-03-18
$26.37K
10-Q · filed 2012-05-09
$172.21K
derived: sum of 2 quarters · filed 2013-03-18
$211.54K
derived: sum of 3 quarters · filed 2013-03-18
$267.48K
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$52.09K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$91.42K
derived: sum of 2 quarters · filed 2013-03-18
$147.36K
derived: sum of 3 quarters · filed 2013-03-18
$213.92K
10-K · filed 2013-03-18
2010-09-30$39.33K
10-Q · filed 2011-11-07
$95.27K
derived: sum of 2 quarters · filed 2011-11-07
$161.82K
10-Q · filed 2011-11-07
2010-06-30$55.94K
10-Q · filed 2011-08-05
$122.50K
10-Q · filed 2011-08-05
2009-12-31$4.93M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
MEDICINOVA INC (MNOV)United States$0.130B-6.04
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Immuneering Corp (IMRX)United States$0.113B-12.51